Cost-effectiveness of inclisiran in patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective.

<h4>Background</h4>Atherosclerotic cardiovascular disease (ASCVD) imposes a substantial clinical and economic burden in China. Despite maximally tolerated statin therapy, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets. Inclisiran, a novel small interfer...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mochou Liu, Xinyue Zhang, Mengwen Feng, Qingfeng He, Zhen Feng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2026-01-01
Colecção:	PLoS ONE
Acesso em linha:	https://doi.org/10.1371/journal.pone.0350294
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!